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Abstract
Background: The US Preventive Services Taskforce (USPSTF) recommends routine lipid screening beginning age 35
for men [1]. For women age 20 and older, as well as men age 20–34, screening is recommended if cardiovascular
risk factors are present. Prior research has focused on underutilization but not overuse of lipid testing. The objective
is to document over- and under-use of lipid testing in an insured population of persons at low, moderate and high
cardiovascular disease (CVD) risk for persons not already on statins.
Methods: The study is a retrospective cohort study that included all adults without prior CVD who were
continuously enrolled in a large integrated healthcare system from 2005 to 2010.
Measures included lipid test frequency extracted from administrative data and Framingham cardiovascular risk
equations applied using electronic medical record data. Five year lipid testing patterns were examined by age,
sex and CVD risk. Generalized linear models were used to estimate the relative risk for over testing associated
with patient characteristics.
Results: Among males and females for whom testing is not recommended, 35.8 % and 61.5 % received at least
one lipid test in the prior 5 years and 8.4 % and 24.4 % had two or more.
Over-testing was associated with age, race, comorbidity, primary care use and neighborhood income. Among
individuals at moderate and high-risk (not already treated with statins) and for whom screening is recommended,
between 21.4 % and 25.1 % of individuals received no screening in the prior 5 years.
Conclusions: Based on USPSTF lipid screening recommendations, this study documents substantial over-testing
among individuals with low CVD risk and under-testing among individuals with moderate to high-risk not already
on statins. Opportunity exists to better focus lipid screening efforts appropriate to CVD risk.
Keywords: Cholesterol testing, Quality of care, Cardiovascular disease risk
Background
Because hyperlipidemia is a leading risk factor for car-
diovascular disease (CVD) that can be reduced by early
intervention, the US Preventive Service Task Force
(USPSTF) recommends routine lipid screening begin-
ning at age 35 for men [1]. For women age 20 and
older, as well as men age 20–34, screening is only
recommended for persons at increased risk (i.e., dia-
betes, hypertension, tobacco use, obesity, previous per-
sonal history of CVD, or premature family history of
CVD) because, without these risks, the absolute 10-year
CVD risk is small regardless of lipid levels. The USPSTF
also recommends repeat screening for individuals with
CVD risk factors and lipid lowering agents based on
Framingham CVD risk projections.
A recent guideline from the American College of
Cardiologists and American Heart Association (ACC-
AHA) recommends universal lipid screening begin
earlier at age 20 for both men and women [2]. They
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also recommend using an updated global CVD risk
calculator to identify young adults at high long-term
(30 year) risk of cardiac mortality. Estimates of 30-
year risk might be useful for those under age 40 with
established risk factors, but screening in this age
group remains controversial because there is no evi-
dence that long-term use of statins improves CVD
outcomes. The ACC-AHA guideline also encourages
lipid screening using the updated risk calculator and
recommends statins for adults ages 40–75 with a
7.5 % 10-year CVD risk or higher.
While older guidelines endorsed regular monitoring of
low density lipoprotein (LDL) for those on statins, the
new guideline omits this recommendation.
Over the last several decades, there has been consider-
able attention on underutilization of cholesterol screen-
ing [3, 4] and the under-treatment of hyperlipidemia in
persons at risk [5, 6].
Latest published data from the Behavioral Risk Factor
Surveillance Survey show use of cholesterol screening is
increasing in persons aged 18 and older, rising from
72.7 % to 76.0 % between 2005 and 2009 [7]. In addition
to underuse, attention in the research and policy com-
munity has focused on overuse of preventive and other
services where expenses and risks outweigh the benefits.
Research confirms that overuse is widespread [8, 9],
not only resulting in unnecessary costs from testing and
downstream expenditures, but also in psychological and
other risks from over-diagnosis [10]. Because of the risks
involved, most research on overuse of screening and
monitoring has focused on colorectal, breast, cervical
and prostate cancer screening [8, 9]. There has been
little attention to overutilization of lipid screening, par-
ticularly in persons who are at low-risk. One study of
Medicare enrollees [11], almost all of whom are at
moderate- or high-risk, found that multiple testing of
lipids was common and likely unnecessary (i.e., 11.9 %
of patients receiving three or more tests in a 1 year
period). To our knowledge, no studies have examined
overuse of lipid screening among low-risk or younger in-
dividuals, nor the characteristics that are associated with
overuse. However, this examination is relevant. Identify-
ing the under-use of recommended screenings could
improve health outcomes for those at moderate- or
high-risk, while identifying the over-use of screenings
among persons at low-risk could point to opportunities
for lowering population-level health care costs and redu-
cing patient burden.
This investigation is part of the e-Care for Heart
Wellness Study (RC1HL100590-01) [9] and focuses on
the patterns of lipid testing among persons without prior
CVD. The purpose of this study is to document over-
and under-use of lipid testing as recommended by the
USPSTF among an insured population including persons
at low, moderate and high CVD risk. We also examine
characteristics associated with over-testing among low
risk persons.
Methods
Cohort participants received care from Group Health, an
integrated healthcare system in Washington State that pro-
vides coverage and care to approximately 405,000 persons
in an integrated group practice. Participants were adults
aged 25–79 who were continuously enrolled at Group
Health for 5 years between April 1, 2005 and March 31,
2010. Continuous enrollment was defined as having no gap
greater than 45 days. Patients were excluded if they also
had less than one primary care visit in the 2 years between
April 1, 2008 and March 31, 2010 since the cardiovascular
risk estimation relies on data derived from healthcare en-
counters. Patients were also excluded if they had a previous
CVD diagnosis (i.e., myocardial infarction, angina, coron-
ary surgery, cerebrovascular occlusion, transient ischemic
attack, congestive heart failure and peripheral vascular dis-
ease), as lipid testing guidelines are different for those with
existing CVD [2, 6]. We excluded persons with other sig-
nificant diseases including cancer (except non-melanoma
skin cancer), end-stage renal disease, hepatic failure and
dementia because cholesterol testing may not be clinically
relevant for this group. Finally, we also excluded persons
who were dispensed 3-hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase inhibitors (statins, because of the
recommendation for lipid monitoring prior to 2013 [9])
and isotretinoin (one or more prescription fills in the study
period).
To construct the study variables, we extracted data
from Group Health’s electronic clinical and administra-
tive data systems. These databases capture all care pro-
vided to enrollees at Group Health facilities and from
external claims. Demographic variables (including age,
sex, race, zip code and health plan) were extracted from
health plan enrollment records as of April 1, 2010. Using
methods developed by Krieger and colleagues [12], we
created ecological-level income and education variables
by aggregating zip codes into census tracks and merging
them with median household income and education
Census variables. To define rural and urban status, we
used the rural–urban commuting area code schema
(RUCAs, version 2.0) that reflect relative geographic
densities based on population counts and community
patterns [13]. To describe our population’s use of pri-
mary care, we counted the average number of primary
care visits per year (to primary care physicians, nurse
practitioners and physician assistants) across the 5 years.
Finally, we counted the number of lipid tests on different
days performed during the 5 year study period.
Biometric, laboratory and tobacco use data were ex-
tracted from the patient’s clinical data based on the most
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recent recorded value during the study period. In addition
to continuous measures, body mass index was classified as
normal weight (<25.0), overweight (25.0–29.9) and obese
(≥30 kg/m2). Systolic blood pressure was classified as ≤
140, 141–160, 161–180 and >180 mm/Hg. Lipid levels
were based on the most recent value recorded and were
aggregated into clinically-relevant categories of <200,
200–239 and ≥240 mg/dl for total cholesterol (TC); <40,
40–59 and ≥60 mg/dl for high density lipoprotein (HDL);
and <100, 100–129, 130–159, 160–189 and ≥ 190 mg/dl
for LDL. Tobacco status was classified as current smoker
or non-smoker using the tobacco vital sign collected at
the most recent visit. Diabetes was defined as having: two
or more filled prescriptions for insulin or oral agents; one
inpatient or two outpatient diagnoses of diabetes at any
time during their enrollment at Group Health; a fasting
glucose >126 mg/dl confirmed by a second out-of range
test within 1 year; or a random glucose > 200 mg/dl also
confirmed by a second test within 1 year. Treated hyper-
tension was determined by looking for any filled prescrip-
tion for an antihypertensive in the prior year. To measure
comorbidity, we used Resource Utilization Bands (RUBs),
the terminal categories of the Adjusted Clinical Group
(ACG) system [14]. The ACG system is widely used to ad-
just for differences in case-mix among populations receiv-
ing health services in outpatient settings [15, 16].
Using our prior methods [17], we combined age, sex,
systolic blood pressure, treatment for hypertension, dia-
betes status, smoking status, BMI, HDL and TC to calcu-
late 10 year Framingham global CVD risk scores using
both lab-based [6] and BMI-based approaches [17]. As
recommended by the Adult Treatment Panel- III of the
National Cholesterol Education Program (ATP-III) [9], pa-
tients were classified into three CVD risk categories: low
(<10 %), moderate (10–20 %) and high (>20 %) to reflect
standards for lipid management during the study period.
The new ACC-AHA guideline (promulgated after the study
period) encourages statin use for persons aged 40–75 with
CVD risk ≥7.5 %, so we also created a secondary binary risk
variable at this threshold to use in sensitivity analyses. Since
lipid testing was not performed on approximately 40 % of
the population during the study period, we used the BMI-
based risk score as our primary measure of CVD risk [17].
Our prior research found BMI- and lab-based scores to be
concordant in 78.2 % of patients. When discordant, the
BMI-based risk was almost always in a higher category,
with less than 2 % of adults with a BMI-based 10-year CVD
risk of <10 % being reclassified to moderate (10–20 %) or
high-risk (>20 %) based on laboratory testing when both
risking methods were available [17]. Lab-based risk scores
were used to characterize risk for individuals with missing
BMI-based measures (n = 698, 1.2 %).
Demographic characteristics and CVD risk factors were
summarized separately for men and women. To compare
observed testing patterns to guideline recommendations,
we first computed the proportion of patients who received
zero, one, two, or three or more lipid tests during the
prior 5 year period, stratified by age, sex and CVD risk.
Because the USPSTF also recommends lipid testing
among all adults aged 20 and older with diabetes, hyper-
tension, tobacco use, or obesity, we further examined test-
ing patterns for persons with low CVD risk scores with
and without any of these individual risk factors. While the
USPSTF also recommends early testing for persons with a
premature CVD family history, population-based family
history data were not available which prevented our ability
to examine testing relative to this risk factor. Regression
models were used to investigate whether patient charac-
teristics were associated with receiving lipid testing more
frequently than USPSTF recommendations, among those
at low-risk excluding persons with diabetes, hypertension,
tobacco use, or obesity. Over-testing was defined for those
at low CVD risk as one or more test in the past 5 years for
women of any age or men age <35, or two or more tests
for men over 35. Generalized linear models with a log link
and Poisson error distribution were used to estimate the
relative risk of over-testing associated with patient charac-
teristics. All analyses were conducted using Stata/MP ver-
sion 12.0 for Windows statistical software (Stata Corp. LP,
College Station, Texas). All study methods were approved
by the Group Health Human Subjects Review Committee.
Results
Figure 1 outlines the selection of the study subjects. Of
the 111,333 persons who were aged 25–79, continuously
enrolled at Group Health, with at least one visit in the
prior 2 years, we excluded 46.5 % because of prevalent
CVD or other significant disease, or with filled prescrip-
tions for HMG-CoA reductase inhibitors or isotretinoin.
The final study cohort of 59,604 persons was 58.8 % fe-
male with a mean age of 51.1 years (SD 12.3) (Table 1.)
As is characteristic of insured populations in Washing-
ton state, the vast majority were white (83.3 %), lived in
urban settings (97.4 %), and had commercial health in-
surance (79.9 %.) Furthermore, a large portion lived in
neighborhoods which were more than 70 % college edu-
cated (45.6 %) but with median household incomes less
than $60,000 per year (68.7 %) using 2000 census data.
No large differences in demographics were apparent be-
tween men and women.
Based on BMI-based Framingham calculations, most
women (77.1 %) were classified as low-risk (<10 %),
17.1 % were at moderate-risk (10–20 %), and only 5.7 %
were at high-risk (>20 %) and not already prescribed sta-
tin medications. However, among men, the proportions
at moderate (31.9 %) and high-risk (29.2 %) not already
prescribed statins were substantially higher. While the
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proportions of men and women whose last recorded sys-
tolic blood pressures was >140 mmHg were similar
(15.3 % vs. 11.4 %), men were more likely to be smokers
(13.5 % vs. 9.1 %) and be overweight or obese (77.2 % vs.
61.8 %.) No large differences were apparent in the propor-
tions of men or women with diabetes (2.3 % vs. 2.0 %), or
who had hypertension (19.9 % vs. 18.5 %.) When overall
illness burden was summarized with RUB categories,
the majority of the population had a moderate burden
(RUB 3) (52.9 %) and only 9.6 % were classified with
high or very high burdens (RUBs 4–5.) Expected differ-
ences between men and women in TC and HDL levels
were apparent [18].
Given the difference in USPSTF lipid screening recom-
mendations for men and women of different ages and risk
levels [1], Table 2 presents the proportion of subjects who
received lipid testing in the prior 5 years, by age, sex and
CVD risk category. The table presents percentages of pa-
tients who received zero, one, two or three or more lipid
tests during the prior 5 year period. For low-risk men less
than age 35 years for whom cholesterol screening is not
recommended [1], 37.6 % had at least one test in the prior
5 years and 10.7 % had two or more.
Among low-risk women of any age where screening is
also not recommended, these percentages were greater,
with 62.5 % having at least one test and 26.3 % having
two or more in the prior 5 years. For persons at
moderate-risk (10–20 %) who were not already on sta-
tins where the USPSTF recommends cholesterol testing
at least once every 5 years [1], 25.1 % of men and 22.7 %
of women had no cholesterol testing. Among persons at
high-risk not already on statins where yearly testing is
recommended, 21.4 % of men and 22.5 % of women had
no record of lipid testing in the 5 years period. When we
applied the new ACC-AHA guidelines [19], only a small
minority of persons less than 40 shifted from low to
higher risk (185/9,622, 1.9 %) when the new low-risk
cut-point was applied (7.5 % vs. 10 % risk.) Using this
new criterion, 40.6 % persons aged 40 and older at low-
risk (<7.5 %) had one test in the prior 5 years and 28.8 %
had two or more.
Because the USPSTF also recommends screening, regard-
less of aggregate CVD risk scores, for all adults 20 years or
older who are obese, use tobacco, or have hypertension or
diabetes, Table 3 presents the study’s main findings and dis-
plays testing for low-risk individuals with none (n = 20,162,
Fig. 1 Study sample
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Table 1 Population characteristics
Men Women
Total, N (row%) 24,540 (41.2) 35,064 (58.8)
n (col%) n (col%)
Age
25–34 2,306 (9.4) 3,697 (10.5)
35–44 5,290 (21.6) 7,242 (20.7)
45–54 7,133 (29.1) 9,946 (28.4)
55–64 6,700 (27.3) 9,063 (25.9)
65–79 3,111 (12.7) 5,116 (14.6)
Cardiovascular riska
Low (<10 %) 7,661 (38.9) 24,192 (77.1)
Moderate (10–20 %) 6,290 (31.9) 5,378 (17.1)
High (>20 %) 5,745 (29.2) 1,798 (5.7)
Missing 4,844 [19.7] 3,696 [10.5]
Diabetes 552 (2.3) 710 (2.0)
BP-lowering medications,
any fill in past year
4,870 (19.9) 6,477 (18.5)
Systolic blood pressure
≤140 18,265 (84.7) 28,956 (88.6)
141–160 2,817 (13.1) 3,103 (9.5)
161–180 438 (2.0) 537 (1.6)
>180 56 (0.3) 91 (0.3)
Missing 2,964 [12.1] 2,377 [6.8]
Total cholesterol
<200 6,745 (46.5) 8,781 (41.0)
200–239 5,508 (38.0) 8,352 (39.0)
≥240 2,256 (15.6) 4,273 (20.0)
Missing 10,031 [40.9] 13,658 [39.0]
HDL cholesterol
<40 2,534 (17.5) 770 (3.6)
40–59 8,135 (56.1) 7,569 (35.4)
≥60 3,838 (26.5) 13,060 (61.0)
Missing 10,033 [40.9] 13,665 [39.0]
LDL cholesterol
<100 2,207 (20.7) 3,721 (24.1)
100–129 3,945 (37.1) 5,808 (37.6)
130–159 3,094 (29.1) 4,049 (26.2)
160–189 1,101 (10.3) 1,467 (9.5)
≥190 302 (2.8) 401 (2.6)
Missing 13,891 [56.6] 19,618 [56.0]
BMI
<25 4,761 (22.8) 12,481 (38.2)
25–29.9 9,220 (44.1) 9.646 (29.5)
≥30 6,913 (33.1) 10,545 (32.3)
Table 1 Population characteristics (Continued)
Missing 3,646 [14.9] 2,392 [6.8]
Current smoker 2,188 (13.5) 3,130 (9.1)
Missing 843 [3.4] 587 [1.7]
RUB
0 = No diagnoses 2,687 (11.0) 2,097 (6.0)
1 = Low 3,519 (14.3) 4,158 (11.9)
2 4,697 (19.1) 5,248 (15.0)
3 11,929 (48.6) 19,557 (55.8)
4 1,355 (5.5) 3,450 (9.8)
5 = High 353 (1.4) 554 (1.6)
Health plan
Medicare 3,309 (13.5) 5,382 (15.4)
Medicaid/Basic
Health
315 (1.3) 673 (1.9)
Commercial 19,945 (81.3) 27,699 (79.0)




<1 8,257 (33.7) 6,572 (18.7)
1 to <2 9,326 (38.0) 12,055 (34.4)
2 to <3 4,130 (16.8) 8,255 (23.5)
≥3 2,827 (11.5) 8,182 (23.3)
Residence
Rural 660 (2.7) 914 (2.6)
Urban 23,880 (97.3) 34,150 (97.4)
Race
White 14,866 (84.0) 25,805 (82.8)
Asian 1,418 (8.0) 3,105 (10.0)
Black 916 (5.2) 1,301 (4.2)
Mixed race/Other 490 (2.8) 951 (3.1)





<$40,000 5,371 (21.9) 7,643 (21.9)
$40,000 to <$60,000 11,394 (46.5) 16,410 (46.9)
$60,000 to <$80,000 5,606 (22.9) 8,014 (22.9)
≥$80,000 2,114 (8.6) 2,913 (8.3)
Missing 55 [0.2] 84 [0.2]
Education, % with some
college
<50 % 2,687 (11.0) 3,953 (11.3)
50 % to <60 % 4,096 (16.7) 5,968 (17.1)
60 % to <70 % 6,407 (26.2) 9,215 (26.3)
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63.3 %) versus one or more or of these factors risks
(n = 11,691, 36.7 %.) For low-risk men less than age 35
with no risks, 35.8 % had at least one test and 8.4 %
and two or more.
Similarly, for low-risk women of any age with no risks,
61.5 % had at least one test and 24.4 % had two or more.
Table 4 examines potential determinants of receipt of
testing more frequently than recommended among low-
risk persons (<10 % CVD risk) and with no individual
risk factors. The table presents both unadjusted and ad-
justed relative risks. (The adjusted relative risks are
adjusted for all of the other characteristics listed in the
table.) For women, age was strongly associated with over-
testing with low-risk women in all age categories being
more likely than women aged 25–34 to be tested more fre-
quently than guideline recommended (RR 2.04–3.16.) or
men, age categories 35–44 and 45–54 were associated with
lower likelihood of testing (RR 0.54–0.80) than for men
aged 25–34. For both men and women, non-white race
and averaging at least one primary care visits per year over
the past five years were factors generally associated with a
higher likelihood of testing in the multivariate models.
While neighborhood education levels were not associated
with over-testing among men or women, women in neigh-
borhoods with higher median income had increased risk of
over-testing. Significant comorbidity (RUB 3–5) was asso-
ciated with over-testing among men but not women.
Discussion
Among persons at low-risk for CVD determined through
the BMI-based Framingham calculations, no individual risk
factors (obesity, tobacco use, hypertension, or diabetes),
and under age 35 for men, a substantial proportion of men
(35.8 %) and women (61.5 %) received cholesterol testing
that is not recommended by the USPSTF. Similarly, among
moderate- and high-risk individuals, 24.0 % and 21.6 % of
these persons respectively had no lipid testing, reflecting
under-screening as per guideline recommendations. Taken
together, these findings suggest sizable gaps in targeting
lipid screening across the risk spectrum that result in both
missing prevention opportunities at one end and unneces-
sary screening at the other (particularly for women). While
lipid testing is relatively inexpensive, there may be down-
stream consequences, particularly for those at low-risk,
such as potential distress over an abnormal value [20], or
the time clinicians use to explain results. Additionally
provision of CVD risk information alone, does little to
change risk [21]. Population identification of individuals
likely to be at high-risk for CVD without lipid testing or
not on statins would lead to more efficient and effective use
of clinical resources. We were not able to determine CVD
risk (with lab or BMI-based approach) on approximately
14 % of the study population suggesting that improvements
in electronic vital sign data entry are needed to fully
characterize risk and the need for cholesterol testing.
Many studies have explored factors related to under-
use of lipid testing and CVD risk assessment. However
less is known about the prevalence and factors associ-
ated with over use of lipid testing. Goodwin et al., in a
Medicare population, found that exposure to health re-
ferral region and care by multiple different physicians
was associated with overtesting independent of indication
for testing, co-morbidities and total physician visits [11].
Virini et al. found that almost one third of Veteran’s Ad-
ministration patients with coronary heart disease and who
had attained LDL goals had more than one LDL test over
an 11-month time period [22].
Our study included low risk and younger patients.
Among low-risk persons, factors that are generally asso-
ciated with over-testing include advancing age and more
primary care visits. This finding suggests that care pro-
viders may be more inclined to order, or patients re-
quest, lipid testing if they are older and make frequent
visits, independent of their low risk status. In other
words, providers and patients may be inclined to over-
estimate CVD risk and need for lipid screening, particu-
larly for women, based on age and visit frequency,
leading to greater attention to early and more lipid
screening. This finding suggests that many providers are
not consistently using risk markers and scoring algo-
rithms to guide lipid screening as recommended by the
USPSTF. This is not unexpected given that barriers exist
Table 1 Population characteristics (Continued)
70 % to <80 % 5,973 (24.4) 8,554 (24.5)
≥80 % 5,319 (21.7) 7,289 (20.8)
Missing 58 [0.2] 85 [0.2]
aCVD Risk score based on BMI-based risk calculations. When BMI-risk was
missing, we used lab-based risk calculations (n = 698). The CVD risk equations
are as follows:
BMI-based CVD Risk Equations:
Male, not treated with antihypertensive medications
100*(1-(0.88431^(exp([3.11296*ln(AGE) + 0.79277*ln(BMI) + 1.85508*ln(SBP) +
0.70953*SMOKE + 0.53160*DIAB] -23.9388))))
Male, treated with antihypertensive medications
100*(1-(0.88431^(exp([3.11296* ln(AGE) + 0.79277* ln(BMI) + 1.92672* ln(SBP) +
0.70953* SMOKE + 0.53160* DIAB] -23.9388))))
Female, not treated with antihypertensive medications
100*(1-(0.94833^(exp([2.72107* ln(AGE) + 0.51125* ln(BMI) + 2.81291* ln(SBP) +
0.61868* SMOKE + 0.77763* DIAB] -26.0145))))
Female, treated with antihypertensive medications
100*(1-(0.94833^(exp([2.72107* ln(AGE) + 0.51125* ln(BMI) + 2.88267* ln(SBP) +
0.61868* SMOKE + 0.77763* DIAB] -26.0145))))
Lab-based CVD Risk Equations:
Male, not treated with antihypertensive medications
100*(1-(0.88936^(exp([3.06117*ln(AGE) + 1.12370*ln(TC)+−0.93263*ln(HDL) +
0.65451*SMOKE + 0.57367*DIAB + 1.93303* ln(SBP)]-23.9802))))
Male, treated with antihypertensive medications
100*(1-(0.88936^(exp([3.06117*ln(AGE) + 1.12370*ln(TC)+−0.93263*ln(HDL) +
0.65451*SMOKE + 0.57367*DIAB + 1.99881* ln(SBP)]-23.9802))))
Female, not treated with antihypertensive medications
100*(1-(0.95012^(exp([2.32888*ln(AGE) + 1.20904*ln(TC)+−0.70833*ln(HDL) +
0.52873*SMOKE + 0.69154*DIAB + 2.76157* ln(SBP)] -26.1931))))
Female, treated with antihypertensive medications
100*(1-(0.95012^(exp([2.32888*ln(AGE) + 1.20904*ln(TC)+−0.70833*ln(HDL) +
0.52873*SMOKE + 0.69154*DIAB + 2.82263* ln(SBP)] -26.1931))))
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to using risk calculators (e.g., physicians often have to
manually retrieve and enter the risk details) [23–26] and
they can be difficult for patients to understand [21, 27].
Furthermore, while the national Choosing Wisely cam-
paign has gathered momentum on reducing overuse of
many services [28], cholesterol overtesting is not cur-
rently a core measure.
Our study has some notable limitations. First, it is im-
portant to note however, because we excluded persons
taking statins, we likely underestimated the proportion
of persons at moderate or high-risk who were appropri-
ately screened. Rather, our under-use estimates should
be interpreted as the proportion of moderate or high
risk persons not currently taking a statin who remain
unscreened. Second, our study relied on BMI- rather
than traditional lipid-based CVD risk estimates to clas-
sify individuals into risk categories. While this can create
misclassification bias, we believe that bias to be conser-
vative with respect to over testing in low-risk people
since when the scores differ, the BMI-based scores are
almost always higher [17]. Third, since family history
[29] and socioeconomic risk [30] are independent CVD
predictors but are not incorporated into traditional cal-
culators, physicians may be appropriately screening low-
risk people with positive family histories or who come
from impoverished areas. However, we believe this limi-
tation to be minor since research finds adding these fac-
tors only make slight improvements to population-based
Table 2 Lipid testing in the past 5 years by sex, age & cardiovascular disease (CVD) risk
Row(%) Low CVD risk (<10 %) Moderate CVD risk (10-20 %) High CVD risk (>20 %) Cannot
determine
CVD risk
Lipid tests Lipid tests Lipid tests
a) Men
Age 0 1 2 3+ Total 0 1 2 3+ Total 0 1 2 3+ Total Total
25-34 62.4 26.9 7.4 3.3 1654 50.0 25.0 12.5 12.5 8 0.0 100.0 0.0 0.0 1 643
35-44 43.1 38.1 11.6 7.1 3478 36.9 34.9 16.2 12.1 464 33.3 19.4 16.7 30.6 36 1312
45-54 29.7 42.6 17.5 10.2 2332 27.8 37.1 20.8 14.3 2631 28.3 32.5 19.1 20.2 754 1416
55-64 25.0 40.3 23.5 11.2 196 21.8 37.2 23.3 17.6 2909 21.4 33.7 23.0 21.9 2478 1117
65-79 0.0 0.0 100.0 0.0 1 14.0 29.1 28.4 28.4 278 19.1 28.1 24.4 28.4 2476 356
Total 42.7 37.1 12.8 7.4 7661 25.1 36.7 21.9 16.3 6290 21.4 31.1 23.1 24.5 5745 4844
b) Women
Age 0 1 2 3+ Total 0 1 2 3+ Total 0 1 2 3+ Total Total
25-34 70.1 21.9 4.9 3.3 3259 0 0 438
35-44 47.0 35.2 11.6 6.3 6436 31.2 16.9 16.9 35.1 77 0.0 80.0 0.0 20.0 5 724
45-54 29.2 41.3 19.3 10.3 7993 29.0 34.4 20.1 16.5 780 18.1 22.3 22.3 37.2 94 1079
55-64 22.4 38.7 23.0 15.8 5485 21.2 33.9 26.3 18.6 2180 21.8 26.6 22.6 29.1 399 999
65-79 20.1 35.5 25.6 18.7 1019 21.7 32.4 24.6 21.3 2341 23.1 32.0 19.8 25.2 1300 456
Total 37.5 36.2 16.4 9.9 24192 22.7 33.1 24.5 19.7 5378 22.5 20.4 20.5 26.6 1798 3696
Yellow shading indicates more testing than recommended by the United States Preventive Services Task Force (USPSTF) for persons with low CVD risk. Green
shading indicates less testing than recommended for persons at moderate- and high-risk and who are not already on statins. Cross-hatch lines signify risk
categories with no study subjects
Table 3 Lipid testing in the past 5 years for adults with low
cardiovascular disease (CVD) risk (<10 %) by number of CVD risk
factors
Row(%) No risk factors 1-4 risk factors
Lipid tests Lipid tests
a) Men
Age 0 1 2 3+ Total 0 1 2 3+ Total
25-34 64.2 27.4 6.4 2.0 891 60.3 26.3 8.5 4.9 763
35-44 41.6 40.2 11.6 6.6 2040 45.3 35.2 11.7 7.9 1438
45-54 29.3 43.3 18.0 9.4 1853 31.3 39.9 15.5 13.4 479
55-64 25.5 40.1 23.4 10.9 192 0.0 50.0 25.0 25.0 4
65-79 0.0 0.0 100.0 0.0 1 0
Total 40.4 39.0 13.5 7.0 4977 47.0 33.5 11.5 8.0 2684
b) Women
Age 0 1 2 3+ Total 0 1 2 3+ Total
25-34 74.8 19.6 3.4 2.2 2017 62.3 25.5 7.2 5.0 1242
35-44 50.6 35.0 10.1 4.3 3730 42.1 35.4 13.6 8.9 2706
45-54 29.9 43.4 18.4 8.3 4708 28.1 38.1 20.7 13.1 3285
55-64 22.4 40.4 22.1 15.2 3869 22.5 34.8 25.3 17.5 1616
65-79 20.4 37.2 24.4 18.0 861 18.4 26.6 32.3 22.8 158
Total 38.5 37.1 15.6 8.8 15,185 35.9 34.8 17.7 11.7 9007
Risk factors include diabetes, treated hypertension, current smoker, body mass
index >30. Yellow shading indicates more testing than recommended by the
United States Preventive Services Task Force (USPSTF) for persons with no risk
factors. Green shading indicates less testing than recommended for persons
with one or more risk factors and who are not already on statins. Cross-hatch
lines signify risk categories with no study subjects
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Table 4 Factors associated with lipid testing among adults with low cardiovascular risk (<10 %) and no CVD risk factors
Men Women
Total sample Tested more than
recommended
Unadjusted Adjusted Total sample Tested more than
recommended
Unadjusted Adjusted
N n (%) RR (95 % CI) RR (95 % CI) N n (%) RR (95 % CI) RR (95 % CI)
Overall 4977 1266 (25.4) 15185 9341 (61.5)
Age
25–34 891 319 (35.8) Referent Referent 2017 508 (25.2) Referent Referent
35–44 2040 372 (18.2) 0.51 (0.45, 0.58) 0.54 (0.46, 0.63) 3730 1843 (49.4) 1.96 (1.81, 2.13) 2.04 (1.86, 2.24)
45–54 1853 508 (27.4) 0.77 (0.68, 0.86) 0.80 (0.70, 0.92) 4708 3301 (70.1) 2.78 (2.58, 3.01) 2.84 (2.60, 3.11)
55–64 192 66 (34.4) 0.97 (0.78, 1.20) 0.87 (0.68, 1.12) 3869 3004 (77.6) 3.08 (2.85, 3.33) 3.16 (2.89, 3.45)
65–79 1* 1* (100.0) – – 861 685 (79.6) 3.16 (2.91, 3.43) 3.01 (2.64, 3.43)
Race
White 2779 679 (24.4) Referent Referent 11012 6926 (62.9) Referent Referent
Asian 469 181 (38.6) 1.58 (1.38, 1.80) 1.63 (1.43, 1.86) 1915 1356 (70.8) 1.13 (1.09, 1.16) 1.20 (1.16, 1.24)
Black 164 50 (30.5) 1.25 (0.98, 1.59) 1.30 (1.03, 1.65) 383 231 (60.3) 0.96 (0.88, 1.04) 1.09 (1.01, 1.18)
Other 81 17 (21.0) 0.86 (0.56, 1.32) 0.86 (0.55, 1.32) 301 171 (56.8) 0.90 (0.82, 1.00) 1.01 (0.92, 1.11)
RUB
0 = No diagnoses 512 89 (17.4) 0.80 (0.64, 1.02) 0.93 (0.70, 1.23) 786 419 (53.3) 0.89 (0.82, 0.96) 0.89 (0.83, 0.96)
1 = Low 722 156 (21.6) Referent Referent 1879 1127 (60.0) Referent Referent
2 1212 301 (24.8) 1.15 (0.97, 1.36) 1.09 (0.89, 1.33) 2756 1622 (59.9) 0.98 (0.93, 1.03) 0.97 (0.93, 1.02)
3 2312 651 (28.2) 1.30 (1.12, 1.52) 1.21 (1.00, 1.45) 8382 5375 (64.1) 1.07 (1.03, 1.11) 1.01 (0.97, 1.05)
4 or 5 = High 219 69 (31.5) 1.46 (1.15, 1.85) 1.38 (1.05, 1.82) 1382 798 (57.7) 0.96 (0.91, 1.02) 0.98 (0.93, 1.04)
Primary care visits (annual avg)
<1 1614 298 (18.5) Referent Referent 2546 1481 (58.2) Referent Referent
1 to <2 2159 568 (26.3) 1.42 (1.26, 1.61) 1.32 (1.14, 1.53) 5950 3721 (62.5) 1.08 (1.03, 1.12) 1.06 (1.02, 1.10)
2 to <3 789 254 (32.2) 1.74 (1.51, 2.01) 1.55 (1.30, 1.84) 3738 2387 (63.9) 1.10 (1.05, 1.14) 1.10 (1.05, 1.14)
≥3 415 146 (35.2) 1.91 (1.61, 2.25) 1.59 (1.30, 1.95) 2951 1752 (59.4) 1.02 (0.98, 1.07) 1.06 (1.02, 1.11)
Residence
Rural 79 19 (24.1) 0.94 (0.64, 1.40) 1.11 (0.74, 1.65) 325 198 (60.9) 0.99 (0.91, 1.08) 1.04 (0.96, 1.13)
Urban 4898 1247 (25.5) Referent Referent 14860 9143 (61.5) Referent Referent
Health plan
Medicare 60 18 (30.0) 1.17 (0.79, 1.73) 1.11 (0.73, 1.69) 966 755 (78.2) 1.29 (1.25, 1.34) 1.06 (0.96, 1.17)
Medicaid/Basic Hlth 83 19 (22.9) 0.89 (0.60, 1.33) 0.97 (0.66, 1.44) 326 168 (51.5) 0.85 (0.77, 0.95) 0.92 (0.84, 1.01)














Table 4 Factors associated with lipid testing among adults with low cardiovascular risk (<10 %) and no CVD risk factors (Continued)
Private pay 224 49 (21.9) 0.85 (0.66, 1.10) 0.76 (0.54, 1.07) 699 449 (64.2) 1.06 (1.00, 1.13) 1.02 (0.97, 1.08)
Neighborhood income, median
<$40,000 1138 287 (25.2) Referent Referent 2974 1439 (48.4) Referent Referent
$40,000–<$60,000 2349 588 (25.0) 0.99 (0.88, 1.12) 1.00 (0.86, 1.16) 6953 4340 (62.4) 1.29 (1.24, 1.34) 1.20 (1.15, 1.25)
$60,000–<$80,000 1088 263 (24.2) 0.96 (0.83, 1.11) 1.03 (0.86, 1.23) 3705 2444 (66.0) 1.36 (1.30, 1.42) 1.22 (1.17, 1.28)
≥$80,000 390 124 (31.8) 1.26 (1.06, 1.50) 1.24 (0.98, 1.56) 1512 1091 (72.2) 1.49 (1.42, 1.57) 1.29 (1.23, 1.37)
Neighborhood education, % with some college
<50 % 471 135 (28.7) Referent Referent 1376 786 (57.1) Referent Referent
50 % to <60 % 722 180 (24.9) 0.87 (0.72, 1.05) 0.92 (0.74, 1.15) 2251 1285 (57.1) 1.00 (0.94, 1.06) 0.95 (0.90, 1.01)
60 % to <70 % 1290 321 (24.9) 0.87 (0.73, 1.03) 0.96 (0.78, 1.17) 3772 2251 (59.7) 1.04 (0.99, 1.10) 0.95 (0.90, 1.00)
70 % to <80 % 1276 318 (24.9) 0.87 (0.73, 1.03) 0.90 (0.73, 1.11) 3938 2497 (63.4) 1.11 (1.05, 1.17) 0.96 (0.91, 1.01)
≥80 % 1205 308 (25.6) 0.89 (0.75, 1.06) 0.90 (0.72, 1.13) 3806 2494 (65.5) 1.15 (1.09, 1.21) 0.93 (0.88, 0.98)















risk categorization [30, 31]. Finally, since the study takes
place in an integrated delivery system with a history of ap-
plying evidence-based prevention guidelines [32], our re-
sults likely underestimate the degree of mismatch between
CVD risk and lipid testing to be found in other practice
settings. The study participants were also largely white
and had health insurance which may limit out study’s
generalizability.
Conclusion
Our study findings clearly highlight the opportunity to
improve adherence to USPSTF screening guidelines.
In so doing, physicians may reduce unnecessary med-
ical costs and burden for a significant subset of patients,
while improving care for others.
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